The FDA approved a new monthly self-injection drug for multiple sclerosis.

The U.S. Food and Drug Administration (FDA) has approved a new drug called Kesimpta (ofatumumab) for adults with relapsing forms of multiple sclerosis (MS). This includes people with clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. Kesimpta is a type of treatment that works by targeting certain immune system cells called B-cells. It is given as an injection under the skin, and after the first few doses, patients can administer it themselves at home once a month. This approval means there is now another self-administered option for people living with these forms of MS. The decision was based on two large studies that compared Kesimpta to another common MS pill over about two years. The studies showed it was effective at reducing the frequency of MS relapses. It's important to know that starting this treatment involves some safety steps. Before beginning, doctors will check for certain health factors, like Hepatitis B and immune system protein levels. Also, the very first injection is recommended to be done with the help of a healthcare professional. As with any new treatment, this approval is a step forward, but it is not a cure for MS. The most important thing for patients to remember is that treatment decisions are personal. Anyone interested in this new option should have a thorough conversation with their own doctor to see if it might be right for their individual situation.